open access publication

Article, 2023

PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2

Hematological Oncology, ISSN 1099-1069, 0278-0232, Volume 41, S2, Pages 849-850, 10.1002/hon.3166_ot28

Contributors

Sehn, Laurie Helen 0000-0003-1860-9765 [1] Chamuleau, Martine E D 0000-0002-0123-9182 [2] Lenz, Georg [3] Clausen, Michael Roost 0000-0003-3218-3633 [4] Haioun, Corinne 0000-0003-0095-5379 [5] Izutsu, Koji 0000-0001-9129-8057 [6] Davies, Andrew John John [7] Zhu, Jun [8] Oki, Toshiko [9] Szafer-Glusman, Edith [9] Conlon, Rebekah [9] Chiou, Hueiyu [9] Ipe, David [9] Elliot, Brian [10] Wu, Jun [9] Salles, Gilles Andre 0000-0002-9541-8666 [11]

Affiliations

  1. [1] BC Cancer Agency
    2. [NORA names: Canada; America, North; OECD];
  2. [2] Vrije Universiteit Amsterdam
    3. [NORA names: Netherlands; Europe, EU; OECD];
  3. [3] University Hospital Münster
    4. [NORA names: Germany; Europe, EU; OECD];
  4. [4] Lillebaelt Hospital
    5. [NORA names: Region of Southern Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
  5. [5] Hôpitaux Universitaires Henri-Mondor
    6. [NORA names: France; Europe, EU; OECD];

Keywords

DLBCL, EPCOR, Large, R-CHOP, epcoritamab, lymphoma, newly, patients, phase

Data Provider: Digital Science

LINKS
-

Matching Records in NORA

  • No Matches Found

SUBJECTS
+

METRICS
+